Katherine Clifton

Medicine & Life Sciences

1. palbociclib 100%
2. Circulating Tumor DNA 96%
3. Breast Neoplasms 91%
4. Triple Negative Breast Neoplasms 75%
5. Geriatrics 42%
6. Mutation 40%
7. ErbB Receptors 39%
8. Clinical Trials 39%
9. Progression-Free Survival 37%
10. Neoplasms 35%
11. Letrozole 34%
12. thymidine kinase 1 34%
13. pembrolizumab 29%
14. Lobular Carcinoma 28%
15. Neoadjuvant Therapy 27%
16. Loneliness 26%
17. Drug Therapy 26%
18. Social Isolation 25%
19. Neoplasm Metastasis 25%
20. Bone Neoplasms 25%
21. Breast 25%
22. Trastuzumab 24%
23. Therapeutics 23%
24. Carboplatin 23%
25. Docetaxel 23%
26. Population 22%
27. Geriatric Assessment 22%
28. Pandemics 22%
29. Bone and Bones 21%
30. Social Support 20%
31. Survival 20%
32. Hormones 17%
33. Appointments and Schedules 16%
34. Fasting 16%
35. Clone Cells 16%
36. Histology 14%
37. Neutropenia 13%
38. Colorectal Neoplasms 13%
39. Guidelines 13%
40. Medical Oncology 12%
41. Whole Exome Sequencing 11%
42. RNA Sequence Analysis 11%
43. Genes 11%
44. Confidence Intervals 11%
45. Disease-Free Survival 11%
46. Ductal Carcinoma 10%
47. Odds Ratio 10%
48. Residual Neoplasm 10%
49. Serum 9%
50. taxane 9%